SEC For	m 4															
FORM 4 U			JNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL		
Section 16. Form 4 or Form 5 obligations may continue. See				Filed pu	Pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								Estimate	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5		
1. Name and Address of Reporting Person <sup>*</sup> Melian Agustin					2. Issuer Name and Ticker or Trading Symbol <u>Allovir, Inc.</u> [ ALVR ]							ck all applica Director	able)	ing Person(s) to Issuer 10% Owner Other (specify		
(Last) (First) (Middle) C/O ALLOVIR, INC. 139 MAIN STREET, SUITE 500					3. Date of Earliest Transaction (Month/Day/Year) 07/29/2020							X Officer (give title Other (specify below) below) Chief Medical Officer				
(Street) CAMBRIDGE MA 02142				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							<ul> <li>S. Individual or Joint/Group Filing (Check Applicable Line)</li> <li>X Form filed by One Reporting Person</li> <li>Form filed by More than One Reporting Person</li> </ul>				
(City) (State) (Zip)																
		Та	ble I - Non-D	erivati	ve Se	ecurities	s Ac	quired, D	isposed o	of, or Ber	neficially	Owned				
1. Title of Security (Instr. 3) Date (Month/D			te	Execution Date,			, Transaction Disposed Of ( Code (Instr.		ities Acquire d Of (D) (Insl	ies Acquired (A) or Of (D) (Instr. 3, 4 and 5)		s F Ily ( ollowing (	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code V	Amount	(A) or (D)	Price	Reported Transacti (Instr. 3 a	on(s)		(Instr. 4)	
			Table II - De (e.g	rivativo g., pute	e Sec s, cal	urities Is, warr	Acq ants	uired, Dis , options,	posed of converti	, or Bene ble secu	eficially ( rities)	Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and of Securitie Underlying Derivative (Instr. 3 an	es J Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	y Direct (D) or Indirec (I) (Instr.	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
Stock Option (Right to Buy)	\$17	07/29/2020		A		220,700		(1)	07/29/2030	Common Stock	220,700	\$0.00	220,700	) D		

Explanation of Responses:

1. 25% of this option shall vest and become exercisable on July 29, 2021, with the remainder vesting in twelve equal quarterly installments thereafter.

**Remarks:** 

## /s/ Brett Hagen, as Attorney-in-Fact 07/31/2020

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.